Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme
Class IITerminatedD-1406-2020

Drug recall · July 29, 2020

Cefdinir for Oral Suspension USP recall

Why: Superpotent Drug: Out-of-specification (OOS) result observed in an assay test of retention samples.

Class II: could cause temporary or reversible health problems; serious harm is remote.

The recall

Product

Cefdinir for Oral Suspension USP, 250 mg/5mL, packaged in 60 mL bottles, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland, Manufactured by: Lupin Limited, Mandideep, India, NDC 68180-723-20

Lots / codes

Lot # F802189, Exp 10/2020, F900240, Exp 1/2021

Quantity
35,928 bottles
Company
Lupin Pharmaceuticals Inc., Baltimore, MD
Distribution
U.S.A. Nationwide
Initiated
July 2, 2020 · Voluntary: Firm initiated
Classified
July 23, 2020
Reported
July 29, 2020
Ended
June 30, 2021
How notified
Letter

The drug: prices, other makers, shortages

If you have this product

  1. Check the lot number on your package against the lots above. Only those lots are recalled.
  2. Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
  3. Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
  4. Return or dispose of recalled product as the company or your pharmacy advises.

Questions about this recall

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Watch Cefdinir

One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.